Risk of atrial fibrillation associated with use of bisphosphonates and other drugs against osteoporosis: a cohort study.
Vestergaard
Peter
P
Department of Endocrinology and Metabolism C, Aarhus University Hospital, Tage Hansens Gade 2, 8000 Arhus C, Denmark. p-vest@post4.tele.dk
Schwartz
Kristoffer
K
Pinholt
Else Marie
EM
Rejnmark
Lars
L
Mosekilde
Leif
L
D000368:Aged; D019386:Alendronate / Q000008:administration & dosage; D001281:Atrial Fibrillation / Q000139:chemically induced / Q000453:epidemiology* / Q000503:physiopathology; D001282:Atrial Flutter / Q000139:chemically induced / Q000453:epidemiology* / Q000503:physiopathology; D050071:Bone Density Conservation Agents / Q000008:administration & dosage*; D015331:Cohort Studies; D015897:Comorbidity; D015986:Confounding Factors, Epidemiologic; D003718:Denmark / Q000453:epidemiology; D004164:Diphosphonates / Q000008:administration & dosage*; D012968:Etidronic Acid / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000503:physiopathology; D029424:Pulmonary Disease, Chronic Obstructive / Q000453:epidemiology; D020849:Raloxifene Hydrochloride / Q000008:administration & dosage; D012189:Retrospective Studies; D012307:Risk Factors
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D020849:Raloxifene Hydrochloride; D012968:Etidronic Acid; D019386:Alendronate